RAPT - RAPT Therapeutics Inc Stock Price, Fair Value and News

4.14USD-0.26 (-5.91%)Delayed as of 14 May 2024, 12:05 pm ET

Market Summary

USD4.14-0.26

Delayedas of 14 May 2024, 12:05 pm

-5.91%

RAPT Stock Price

View Fullscreen

RAPT RSI Chart

RAPT Valuation

Market Cap

153.6M

Price/Earnings (Trailing)

-1.3

Price/Sales (Trailing)

106.29

EV/EBITDA

-1.72

Price/Free Cashflow

-1.45

RAPT Price/Sales (Trailing)

RAPT Profitability

EBT Margin

-4532.02%

Return on Equity

-90.23%

Return on Assets

-75.76%

Free Cashflow Yield

-68.99%

RAPT Fundamentals

RAPT Revenue

Revenue (TTM)

1.5M

RAPT Earnings

Earnings (TTM)

-118.0M

Earnings Growth (Yr)

-4.27%

Earnings Growth (Qtr)

1.15%

Breaking Down RAPT Revenue

52 Week Range

4.1025.78

(Low)(High)

Last 7 days

-47.1%

Last 30 days

-52.3%

Last 90 days

-82.5%

Trailing 12 Months

-76.9%

How does RAPT drawdown profile look like?

RAPT Financial Health

Current Ratio

7.01

RAPT Investor Care

Shares Dilution (1Y)

1.63%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2022	3.2M	3.2M	2.3M	1.5M
2021	5.3M	4.9M	4.4M	3.8M
2020	0	0	0	5.0M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of RAPT Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jan 05, 2024	brockstedt dirk g.	sold	-20,456	22.78	-898	chief scientific officer
Dec 29, 2023	brockstedt dirk g.	acquired	49,440	6.18	8,000	chief scientific officer
Dec 21, 2023	ho william	sold	-54,200	21.68	-2,500	chief medical officer
Nov 28, 2023	ho william	sold	-20,580	13.72	-1,500	chief medical officer
Oct 03, 2023	ho william	sold	-39,425	15.77	-2,500	chief medical officer
Aug 18, 2023	ho william	sold	-47,300	18.92	-2,500	chief medical officer
Jul 28, 2023	ho william	acquired	5,520	12.00	460	chief medical officer
Jun 23, 2023	ho william	acquired	11,040	12.00	920	chief medical officer
Apr 19, 2023	ho william	sold	-94,400	18.88	-5,000	chief medical officer
Apr 13, 2023	ho william	acquired	5,520	12.00	460	chief medical officer

Which funds bought or sold RAPT recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 10, 2024	CITIGROUP INC	reduced	-86.58	-926,761	47,235	-%
May 10, 2024	ACADIAN ASSET MANAGEMENT LLC	new	-	97,000	97,000	-%
May 10, 2024	VANGUARD GROUP INC	added	21.23	-28,711,300	22,385,800	-%
May 10, 2024	CenterBook Partners LP	sold off	-100	-781,458	-	-%
May 10, 2024	WELLS FARGO & COMPANY/MN	added	54.45	-137,142	173,234	-%
May 10, 2024	DIMENSIONAL FUND ADVISORS LP	added	14.03	-7,135,230	5,000,100	-%
May 10, 2024	OSAIC HOLDINGS, INC.	sold off	-100	-19,647	-	-%
May 10, 2024	CREDIT SUISSE AG/	added	0.09	-593,630	336,382	-%
May 10, 2024	Campbell & CO Investment Adviser LLC	sold off	-100	-328,343	-	-%
May 10, 2024	CHESAPEAKE CAPITAL CORP /IL/	sold off	-100	-253,768	-	-%

Are Funds Buying or Selling RAPT?

Are funds buying RAPT calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own RAPT

No. of Funds

Unveiling RAPT Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	deep track capital, lp	5.22%	1,793,966	SC 13G/A
Feb 14, 2024	price t rowe associates inc /md/	9.9%	3,413,552	SC 13G/A
Feb 14, 2024	redmile group, llc	9.9%	3,776,847	SC 13G/A
Feb 14, 2024	perceptive advisors llc	6.2%	2,139,950	SC 13G/A
Feb 13, 2024	vanguard group inc	5.98%	2,056,221	SC 13G
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Jan 26, 2024	blackrock inc.	7.1%	2,453,049	SC 13G/A
Jan 23, 2024	state street corp	4.23%	1,454,556	SC 13G/A
Oct 23, 2023	deep track capital, lp	5.80%	1,991,403	SC 13G
Jun 12, 2023	price t rowe associates inc /md/	10.4%	3,556,462	SC 13G/A

Recent SEC filings of RAPT Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
May 09, 2024	10-Q	Quarterly Report
May 09, 2024	8-K	Current Report
Apr 05, 2024	ARS	ARS
Apr 05, 2024	DEF 14A	DEF 14A
Apr 05, 2024	DEFA14A	DEFA14A
Apr 01, 2024	4	Insider Trading
Apr 01, 2024	4	Insider Trading
Apr 01, 2024	4	Insider Trading
Mar 07, 2024	8-K	Current Report
Mar 07, 2024	10-K	Annual Report

Peers (Alternatives to RAPT Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	48.2B	6.8B	19.54%	-2.80%	-8.07	7.03	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	19.0B	2.0B	0.98%	-26.98%	-57.12	9.47	75.20%	68.82%
BMRN	15.3B	2.5B	-12.72%	-14.31%	74.39	6.18	13.74%	186.89%
INCY	12.9B	3.8B	6.98%	-11.75%	17.35	3.43	8.58%	129.81%
MID-CAP
BBIO	5.3B	107.9M	6.22%	110.41%	-9.76	48.09	54.84%	-28.31%
APLS	5.2B	524.1M	-16.95%	-51.10%	-12.51	9.96	394.93%	39.61%
AXSM	3.6B	251.0M	9.36%	-4.29%	-12.12	14.31	73.58%	-86.73%
ARWR	2.7B	240.7M	-10.69%	-43.90%	-5.82	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-11.38%	-29.25%	-1.5K	3.08	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	6.64%	20.67%	29.44	4.66	60.38%	-34.49%
NVAX	1.8B	996.6M	206.31%	55.15%	-4.62	1.85	-26.66%	65.49%
CRBP	458.7M	881.7K	5.07%	336.18%	-13.59	481.06	-77.61%	33.36%
INO	294.6M	4.9M	3.08%	29.79%	-2.36	60.54	-54.97%	48.23%
IBIO	15.6M	2.1M	-10.40%	79.21%	-0.67	7.61	-13.45%	69.54%

RAPT Therapeutics Inc News

Latest updates

RAPT Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1
Revenue	-	-	-	886,000	641,000	756,000	966,000	869,000	1,222,000	1,302,000	1,528,000	1,277,000	935,000
Operating Expenses	12.7%	24,431,000	21,678,000	19,795,000	21,418,000	18,790,000	19,499,000	16,950,000	17,783,000	14,387,000	16,109,000	13,788,000	13,972,000
S&GA Expenses	-2.0%	4,977,000	5,079,000	5,436,000	4,748,000	4,491,000	3,774,000	3,760,000	4,012,000	3,483,000	3,197,000	2,802,000	3,289,000
R&D Expenses	17.2%	19,454,000	16,599,000	14,359,000	16,670,000	14,299,000	15,725,000	13,190,000	13,771,000	10,904,000	12,912,000	10,986,000	10,683,000
EBITDA Margin	-49.5%	-44.63	-29.85	-21.01	-21.12	-17.90	-14.43	-11.88	-	-	-	-	-
Income Taxes	-	-	-	-	-	-	-	-	-	199,000	287,000	267,000	237,000
Earnings Before Taxes	-	-	-	-	-	-17,929,000	-18,651,000	-16,110,000	-16,514,000	-12,536,000	-14,344,000	-12,120,000	-12,902,000
EBT Margin	-49.5%	-45.32	-30.31	-21.30	-21.41	-18.15	-14.64	-12.09	-	-	-	-	-
Net Income	-8.1%	-22,951,000	-21,235,000	-19,184,000	-20,468,000	-17,929,000	-18,651,000	-16,110,000	-16,514,000	-12,735,000	-14,631,000	-12,387,000	-13,139,000
Net Income Margin	-59.0%	-54.90	-34.52	-23.46	-22.64	-18.15	-14.68	-12.19	-	-	-	-	-
Free Cashflow	-32.9%	-22,898,000	-17,230,000	-15,761,000	-15,727,000	-21,075,000	-12,589,000	-13,980,000	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-10.1%	156	173	200	221	248	266	209	222	188	199	217	231	106	119	129	140	151	85.00	58.00	62.00	66.00
Current Assets	-8.3%	148	162	187	207	235	253	198	210	176	193	214	228	103	116	126	136	147	81.00	51.00	-	-
Cash Equivalents	-4.6%	45.00	47.00	54.00	50.00	46.00	39.00	28.00	57.00	32.00	24.00	60.00	86.00	25.00	25.00	20.00	29.00	92.00	77.00	48.00	-	-
Net PPE	-8.5%	2.00	2.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	4.00	4.00	4.00	-	-
Liabilities	-5.0%	25.00	26.00	27.00	21.00	28.00	21.00	20.00	20.00	20.00	12.00	16.00	14.00	14.00	15.00	-	-	-	11.00	-	-	-
Current Liabilities	-3.1%	21.00	22.00	22.00	15.00	22.00	14.00	14.00	13.00	12.00	10.00	13.00	10.00	11.00	12.00	16.00	13.00	13.00	9.00	5.00	-	-
Shareholder's Equity	-11.0%	131	147	173	200	220	245	189	202	168	186	202	218	92.00	104	110	123	132	73.00	-	-	-
Retained Earnings	-6.3%	-515	-484	-453	-422	-397	-367	-344	-323	-304	-284	-266	-247	-231	-214	-202	-187	-175	-161	-148	-	-
Additional Paid-In Capital	2.3%	646	632	627	622	617	613	535	527	473	471	468	465	323	319	312	310	307	235	24.00	-	-
Shares Outstanding	-100.0%	-	34.00	38.00	38.00	38.00	34.00	34.00	30.00	30.00	30.00	29.00	25.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	399	-	-	-	319	-	-	-	622	-	-	-	437	-	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	2.2%	-27,084	-27,706	-21,884	-28,808	-18,602	-22,849	-17,149	-15,195	-15,578	-20,681	-12,519	-13,916	-13,910	-15,366	-9,953	-6,427	-8,745	-5,688	-12,139	-9,013	-8,634
Share Based Compensation	21.9%	5,398	4,429	4,329	4,239	4,094	3,025	2,865	2,672	2,702	2,086	2,291	2,888	2,687	2,558	2,005	2,035	2,088	896	431	347	377
Cashflow From Investing	-23.0%	15,887	20,639	25,749	32,437	25,308	-41,270	-17,599	-10,458	23,837	-15,892	-14,174	-63,692	12,411	15,495	1,060	-57,009	-46,981	20.00	-76.00	-368	-419
Cashflow From Financing	1872.9%	9,036	458	106	767	116	75,359	5,251	50,438	132	601	472	139,108	1,301	4,560	165	864	69,872	34,741	663	7,485	7,013
Buy Backs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	65.00	109

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

RAPT Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Revenue	$ 0	$ 1,527
Operating expenses:
Research and development	101,002	67,082
General and administrative	26,060	20,240
Total operating expenses	127,062	87,322
Loss from operations	(127,062)	(85,795)
Other income, net	10,264	1,957
Net loss	(116,798)	(83,838)
Other comprehensive income (loss):
Foreign currency translation gain (loss)	(655)	627
Unrealized gain (loss) on marketable securities	784	(447)
Total comprehensive loss	$ (116,669)	$ (83,658)
Net loss per share, basic	$ (3.05)	$ (2.58)
Net loss per share, diluted	$ (3.05)	$ (2.58)
Weighted average number of shares used in computing net loss per share, basic	38,338,161	32,540,406
Weighted average number of shares used in computing net loss per share, diluted	38,338,161	32,540,406

RAPT Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 47,478	$ 38,946
Marketable securities	111,384	210,122
Prepaid expenses and other current assets	2,920	3,626
Total current assets	161,782	252,694
Property and equipment, net	2,448	2,539
Operating lease right-of-use assets	5,228	6,940
Other assets	3,871	4,036
Total assets	173,329	266,209
Current liabilities:
Accounts payable	5,176	3,365
Accrued expenses	14,103	8,656
Operating lease liabilities, current	2,448	2,171
Other current liabilities	109	32
Total current liabilities	21,836	14,224
Operating lease liabilities, non-current	4,458	6,819
Total liabilities	26,294	21,043
Commitments (see note 6)
Stockholders' equity:
Preferred stock, $0.0001 par value: 50,000,000 shares authorized; no shares issued and outstanding at December 31, 2023 and 2022
Common stock, $0.0001 par value; 500,000,000 shares authorized; 34,398,312 and 34,254,314 shares issued and outstanding at December 31, 2023 and 2022, respectively	3	3
Additional paid-in capital	631,611	613,073
Accumulated other comprehensive gain (loss)	103	(26)
Accumulated deficit	(484,682)	(367,884)
Total stockholders' equity	147,035	245,166
Total liabilities and stockholders' equity	$ 173,329	$ 266,209

About RAPT Therapeutics Inc

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. The company's lead oncology drug candidate is FLX475, an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. It also focuses on the development of hematopoietic progenitor kinase 1 inhibitor. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

CEO	Dr. Brian Russell Wong M.D., Ph.D.
WEBSITE	rapt.com
INDUSTRY	Biotechnology
EMPLOYEES	122

RAPT Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for RAPT Therapeutics Inc? What does RAPT stand for in stocks?

RAPT is the stock ticker symbol of RAPT Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of RAPT Therapeutics Inc (RAPT)?

As of Mon May 13 2024, market cap of RAPT Therapeutics Inc is 153.58 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of RAPT stock?

You can check RAPT's fair value in chart for subscribers.

What is the fair value of RAPT stock?

You can check RAPT's fair value in chart for subscribers. The fair value of RAPT Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of RAPT Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for RAPT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is RAPT Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether RAPT is over valued or under valued. Whether RAPT Therapeutics Inc is cheap or expensive depends on the assumptions which impact RAPT Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RAPT.

What is RAPT Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon May 13 2024, RAPT's PE ratio (Price to Earnings) is -1.3 and Price to Sales (PS) ratio is 106.29. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RAPT PE ratio will change depending on the future growth rate expectations of investors.